ArticleScientific reports2025
Alpinetin pretreatment prevents lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by inhibiting ferroptosis via the Nrf2/SLC7A11/GPX4 pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual Roles of Natural Products in Regulating Ferroptosis in Acute and Chronic Liver Diseases: A Review.Oxidative medicine and cellular longevity · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
This study aims to investigate whether alpinetin prevents lipopolysaccharide/D-galactosamine (LPS/D-GalN)-induced acute liver injury (ALI) in mice by inhibiting ferroptosis, and to explore the potential molecular mechanisms involved. Thirty-six male BALB/c mice were randomly assigned to one of six groups (n = 6): the control group, the LPS/D-GalN group, the Ferrostatin-1 (Fer-1) + LPS/D-GalN group, and the alpinetin (12.5, 25, or 50 mg/kg) + LPS/D-GalN groups.The ferroptosis-specific inhibitor Fer-1 was used as a positive control to verify the involvement of ferroptosis in the injury. Following intraperitoneal (i.p.) administration of alpinetin (12.5, 25, or 50 mg/kg) for three consecutive days, acute liver injury was induced by an i.p. injection of LPS (30 µg/kg) and D-GalN (600 mg/kg). The effect of alpinetin on ALI was detected by serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and hematoxylin and eosin (H&E) staining of hepatic tissue. Ferroptosis levels were analyzed by malondialdehyde (MDA), reduced glutathione (GSH), and Fe
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.